141 related articles for article (PubMed ID: 7534147)
1. Modulation of human P-glycoprotein epitope expression by temperature and/or resistance-modulating agents.
Jachez B; Cianfriglia M; Loor F
Anticancer Drugs; 1994 Dec; 5(6):655-65. PubMed ID: 7534147
[TBL] [Abstract][Full Text] [Related]
2. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
3. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.
Boesch D; Loor F
Anticancer Drugs; 1994 Apr; 5(2):229-38. PubMed ID: 7914109
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
Loor F; Tiberghien F; Wenandy T; Didier A; Traber R
J Med Chem; 2002 Oct; 45(21):4598-612. PubMed ID: 12361387
[TBL] [Abstract][Full Text] [Related]
5. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
6. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents.
Lehne G; De Angelis P; den Boer M; Rugstad HE
Leukemia; 1999 May; 13(5):768-78. PubMed ID: 10374882
[TBL] [Abstract][Full Text] [Related]
8. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
9. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.
Pourtier-Manzanedo A; Didier AD; Muller CD; Loor F
Anticancer Drugs; 1992 Aug; 3(4):419-25. PubMed ID: 1421439
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
11. Topology of MDR1-P-glycoprotein as indicated by epitope mapping of monoclonal antibodies to human MDR cells.
Cianfriglia M; Poloni F; Signoretti C; Romagnoli G; Tombesi M; Felici F
Cytotechnology; 1996; 19(3):247-51. PubMed ID: 8862014
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein epitope mapping. I. Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multi-drug-resistant cells.
Cianfriglia M; Willingham MC; Tombesi M; Scagliotti GV; Frasca G; Chersi A
Int J Cancer; 1994 Jan; 56(1):153-60. PubMed ID: 7505264
[TBL] [Abstract][Full Text] [Related]
13. Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells.
Meschini S; Marra M; Condello M; Calcabrini A; Federici E; Dupuis ML; Cianfriglia M; Arancia G
Int J Oncol; 2005 Dec; 27(6):1597-603. PubMed ID: 16273216
[TBL] [Abstract][Full Text] [Related]
14. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
15. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia.
Grey MR; Burgess R; Fisher A; Yin JA
Leuk Res; 1999 Jan; 23(1):29-35. PubMed ID: 9933132
[TBL] [Abstract][Full Text] [Related]
16. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein.
Lehne G; De Angelis P; Clausen OP; Egeland T; Tsuruo T; Rugstad HE
Cytometry; 1995 Jul; 20(3):228-37. PubMed ID: 7587708
[TBL] [Abstract][Full Text] [Related]
17. Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation.
Maki N; Hafkemeyer P; Dey S
J Biol Chem; 2003 May; 278(20):18132-9. PubMed ID: 12642584
[TBL] [Abstract][Full Text] [Related]
18. Detection of P-glycoprotein in cell lines and leukemic blasts: failure of select monoclonal antibodies to detect clinically significant Pgp levels in primary cells.
Taylor BJ; Olson DP; Ivy SP
Leuk Res; 2001 Dec; 25(12):1127-35. PubMed ID: 11684287
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.
Yano S; Sone S; Nishioka Y; Naito M; Tsuruo T; Ogura T
Jpn J Cancer Res; 1994 Feb; 85(2):194-203. PubMed ID: 7511575
[TBL] [Abstract][Full Text] [Related]
20. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.
Merlin JL; Guerci AP; Marchal S; Bour C; Colosetti P; Kataki A; Guerci O
Br J Haematol; 1998 Nov; 103(2):480-7. PubMed ID: 9827923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
